Ki-67 Labeling Index as a Marker of Malignancy in Ocular Surface Neoplasms

Ohara, Maki; Sotozono, Chie; Tsuchihashi, Yasunari; Kinoshita, Shigeru

doi:10.1007/s10384-004-0129-0

Cited by 30 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evaluation of the risk of relapse based on the clinicopathological features is of limited value. The role of immunoexpression of epithelial growth factor (EGFR) and proliferation index Ki-67 in establishing proper prognosis and choice of further therapy has been stressed [2,3,[12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid

Iljin

Zieliński

Antoszewski

et al. 2016

pdia

View full text Add to dashboard Cite

Introduction Basal cell carcinoma (BCC) is the most common malignant neoplasm of the eyelids and surrounding structures, usually developing in the area of the lower lid and medial canthus. Invasive forms of BCC are connected with a high risk of recurrence, often due to incomplete excision of these lesions. Aim Clinical and pathological analysis of recurrent BCCs of the eyelids and surrounding structures. Material and methods We present clinical and pathological analysis including immunohistochemical reaction to Ki-67 antigen of 19 patients (11 women, 8 men) operated for recurrent BCCs of the eyelids in 2000–2012. Results In most cases, recurrences were present on the lower lid and in the medial canthus. In 15 patients the histopathological type did not change and in 4 cases it transformed into more invasive forms. The values of Ki-67 index for primary BCCs ranged between 1% and 20%, and for relapsing lesions between 11% and 48%. Conclusions Proper clinical and pathological evaluation to determine the risk of relapse in BCCs of the eyelids and surrounding structures should include the analysis of prognostic factors, in particular location and size, histopathological type and radicalness of surgical treatment of primary BCCs. Clinical and pathological analysis of patients with recurrent BCC of the eyelids and surrounding structures should be combined with the evaluation of proliferation index Ki-67, which is essential for prognosis and choice of the appropriate therapeutic method.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid

Iljin

Zieliński

Antoszewski

et al. 2016

pdia

View full text Add to dashboard Cite

show abstract

“…One study compared tissue specimens obtained from SCC, CIN, and non-CIN (pterygium) lesions, revealed that Ki-67 proliferative index (Ki-67 PI) was significantly higher in SCC and CIN than in pterygium. (Ohara et al 2004) In another study, the Ki-67 PI of CINs accounted for 20-48% which was significantly higher than non-CIN lesions (8-12%) and normal conjunctivae (8-12%). This study also showed that there was no statistical significance of P53-positive cells in CIN lesion compared to non-CIN lesions and normal conjunctiva due to the wide standard deviations.…”

Section: Immunohistochemical Analysis: Ki-67 Proliferative Indexmentioning

confidence: 88%

Ocular Surface Squamous Neoplasia

Tananuvat¹,

Lertprasertsuke²

2012

Intraepithelial Neoplasia

View full text Add to dashboard Cite

“…93 In one study that sourced cases and controls from Uganda, a region where the prevalence of HIV infection and sun exposure is high, genetic changes in p53 (consistent with a molecular signature of UV-induced mutagenesis) were identified in 52% of cases and 14% of controls, and DNA from epidermodysplasia HPV in ocular-surface disease N Di Girolamo…”

Section: Role Of Hpv In P53 Tumor-suppressor Inactivationmentioning

confidence: 99%

Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia

Girolamo

2011

Eye

View full text Add to dashboard Cite

There are more microorganisms that colonize the human body than resident cells; some are commensal whereas others are pathogenic. Pathogenic microorganisms are sensed by the innate or adaptive immune system, an immune response is initiated, and the infection is often cleared. Some microorganisms have developed strategies to evade immune defenses, ensuring their long-term survival with potentially devastating consequences for the host. Approximately 18% of all cancers can be attributed to infective agents; the most common being Helicobacter pylori, Human papilloma virus (HPV) and Hepatitis B and C virus in causing stomach, cervical and liver carcinoma, respectively. This review focuses on whether HPV infection is necessary for initiating pterygia, a common benign condition and ocular-surface squamous neoplasia (OSSN), a rare disease with metastatic potential. The search engine PubMed was used to identify articles from the literature related to HPV and pterygium or conjunctival neoplasia. From 34 investigations that studied HPV in pterygia and OSSN, a prevalence rate of 18.6% (136/731) and 33.8% (144/426), respectively, was recorded. The variation in HPV prevalence (0-100%) for both disease groups may have arisen from study-design faults and the techniques used to identify the virus. Overall, the data suggest that HPV is not necessary for initiating either condition but may be a co-factor in susceptible hosts. Currently, over 60 million people worldwide have been immunized with HPV vaccines, but any effect on pterygium and OSSN development may not be known for some time as these lesions can evolve over decades or occur in older individuals.

show abstract

Ki-67 Labeling Index as a Marker of Malignancy in Ocular Surface Neoplasms

Abstract: These results suggest that Ki-67 LI may be a sensitive marker for ocular malignant tumor grading.

Cited by 30 publications

References 28 publications

Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid

Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid

Ocular Surface Squamous Neoplasia

Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia

Contact Info

Product

Resources

About